Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group.
作者信息
Czaja Christopher A, Levin Adrah, Moridani Majid, Krank Jessica L, Curran-Everett Douglas, Anderson Peter L
机构信息
Department of Medicine, National Jewish Health, Denver, Colorado, USA
Department of Medicine, National Jewish Health, Denver, Colorado, USA.
出版信息
Antimicrob Agents Chemother. 2014 Jun;58(6):3570-1. doi: 10.1128/AAC.02763-14. Epub 2014 Apr 14.
Abstract
摘要
相似文献
1
Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group.头孢西丁持续输注治疗脓肿分枝杆菌组引起的肺部感染。
Antimicrob Agents Chemother. 2014 Jun;58(6):3570-1. doi: 10.1128/AAC.02763-14. Epub 2014 Apr 14.
2
[Mycobacterium abscessus pulmonary infection treated with tigecyclin-amikacin and cefoxitin in a diabetic patient].[糖尿病患者中使用替加环素-阿米卡星和头孢西丁治疗脓肿分枝杆菌肺部感染]
Med Mal Infect. 2011 Aug;41(8):446-8. doi: 10.1016/j.medmal.2011.02.011. Epub 2011 Mar 23.
3
A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.与脓肿分枝杆菌肺病患者相比，对马赛分枝杆菌肺病患者而言，较短的治疗疗程可能就足够了。
Respir Med. 2014 Nov;108(11):1706-12. doi: 10.1016/j.rmed.2014.09.002. Epub 2014 Sep 16.
4
The treatment of rapidly growing mycobacterial infections.快速生长分枝杆菌感染的治疗。
Clin Chest Med. 2015 Mar;36(1):67-78. doi: 10.1016/j.ccm.2014.10.004. Epub 2014 Nov 5.
5
Nontuberculous mycobacteria infections in immunosuppressed hosts.免疫抑制宿主中的非结核分枝杆菌感染
Clin Chest Med. 2015 Mar;36(1):91-9. doi: 10.1016/j.ccm.2014.11.002. Epub 2014 Dec 23.
6
Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense.脓肿分枝杆菌和马赛分枝杆菌肺病的进展和治疗结果。
Clin Infect Dis. 2017 Feb 1;64(3):301-308. doi: 10.1093/cid/ciw723. Epub 2016 Nov 10.
7
Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report.采用抗生素成功治疗由脓肿分枝杆菌脓肿亚种引起的肺部疾病，该亚种erm(41)基因第19位发生C到T突变：病例报告
BMC Infect Dis. 2016 May 17;16:207. doi: 10.1186/s12879-016-1554-7.
8
Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.脓肿分枝杆菌肺病的抗生素治疗：65例患者的回顾性分析
Am J Respir Crit Care Med. 2009 Nov 1;180(9):896-902. doi: 10.1164/rccm.200905-0704OC. Epub 2009 Aug 6.
9
Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing.分枝杆菌脓肿感染的临床结果和药敏试验。
J Microbiol Immunol Infect. 2010 Oct;43(5):401-6. doi: 10.1016/S1684-1182(10)60063-1.
10
Antibiotic treatment for nontuberculous mycobacterial lung disease.非结核分枝杆菌肺病的抗生素治疗
Expert Rev Respir Med. 2016;10(5):557-68. doi: 10.1586/17476348.2016.1165611. Epub 2016 Mar 30.
引用本文的文献
1
Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics.头孢菌素类抗生素持续输注的原理与实施安排
Pharmacy (Basel). 2024 Dec 5;12(6):185. doi: 10.3390/pharmacy12060185.
2
Durlobactam to boost the clinical utility of standard of care β-lactams against lung disease.杜洛巴坦可提高标准护理β-内酰胺类药物对肺部疾病的临床效用。
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0104624. doi: 10.1128/aac.01046-24. Epub 2024 Nov 20.
3
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.治疗非结核分枝杆菌感染的药物：来自意大利传染病和热带医学学会分枝杆菌研究组的叙述性综述。
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
4
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.囊性纤维化中非结核分枝杆菌药物治疗的临床药代动力学和药效学考虑因素。
Clin Pharmacokinet. 2021 Sep;60(9):1081-1102. doi: 10.1007/s40262-021-01010-4. Epub 2021 May 13.
本文引用的文献
1
Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease.接受治疗的脓肿分枝杆菌肺病患者的临床和微生物学结局。
Clin Infect Dis. 2011 Mar 1;52(5):565-71. doi: 10.1093/cid/ciq237.
2
Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.非结核分枝杆菌肺病在四个综合医疗保健提供系统中的流行率。
Am J Respir Crit Care Med. 2010 Oct 1;182(7):970-6. doi: 10.1164/rccm.201002-0310OC. Epub 2010 Jun 10.
3
Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.脓肿分枝杆菌肺病的抗生素治疗：65例患者的回顾性分析
Am J Respir Crit Care Med. 2009 Nov 1;180(9):896-902. doi: 10.1164/rccm.200905-0704OC. Epub 2009 Aug 6.
4
A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics.关于持续使用β-内酰胺类抗生素临床益处的系统评价。
Crit Care Med. 2009 Jun;37(6):2071-8. doi: 10.1097/CCM.0b013e3181a0054d.
5
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.美国胸科学会/美国感染病学会官方声明：非结核分枝杆菌病的诊断、治疗与预防
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. doi: 10.1164/rccm.200604-571ST.
6
Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials.抗生素持续静脉输注与间歇静脉输注的比较：随机对照试验的荟萃分析
Lancet Infect Dis. 2005 Sep;5(9):581-9. doi: 10.1016/S1473-3099(05)70218-8.
7
Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.静脉注射头孢美唑和头孢西丁的药代动力学以及丙磺舒对头孢美唑消除的影响。
Antimicrob Agents Chemother. 1989 Mar;33(3):356-61. doi: 10.1128/AAC.33.3.356.
Zotero 插件